People: Invion Ltd (IVX.AX)

IVX.AX on Australia Stock Exchange

12 Nov 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Campbell, James 

Dr. James A. Campbell, Ph.D., is Non-Executive Director of Invion Ltd since October 14, 2013. He served as Executive Director from August 2012 to October 14, 2013, and as Non-Executive Director from February 26, 2012 to August 2012. Dr James Campbell is a senior biotechnology executive with more than 20 years international experience in scientific research, research management, management consulting and venture capital. Dr Campbell has held research positions at the CNRS and the CSIRO. He is a principal of Gemini Biotechnology, a specialist biotechnology advisory services company advising life science companies on M&A, partnering and corporate strategy. Dr Campbell was an executive at ChemGenex Pharmaceuticals for nine years until the company was acquired in 2011. During the previous three years, Dr Campbell has also served as a director of Gemini Biotechnology, Fusion Biosciences Pty Ltd and Vitality Devices.

Basic Compensation

Total Annual Compensation, AUD 127,309
Restricted Stock Award, AUD --
Long-Term Incentive Plans, AUD --
All Other, AUD 23,212
Fiscal Year Total, AUD 150,521

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --